The incorporation of myeloid growth factors into the eviti evidence-based chemotherapy regimens are based on myeloid growth factors guidelines prepared by groups such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Center Network (NCCN) Compendia, and the Multinational Association of Supportive Care in Cancer (MASCC).
High Risk of Febrile Neutropenia - Mandatory
For all regimens with a documented risk of febrile neutropenia ≥ to 20%, eviti expects that a myeloid growth factor will be prescribed with the regimen.
Intermediate Risk of Febrile Neutropenia- Optional
For all regimens with a documented risk of febrile neutropenia between 10% and 19%, eviti expects the addition of growth factor with no justification.
Low Risk of Febrile Neutropenia- Optional With Justification
For all regimens with a documented risk of febrile neutropenia < 10%, eviti expects the addition of growth factors allowed with appropriate justification.
1) The febrile neutropenia risk category is assigned to each regimen based on review of the primary literature for each regimen.
2) The expected dose and schedule of administration of these drugs are based on the product information and above guidelines.
3) The medical policy of some payers may conflict with this approach. This payer-specific policy will be used to evaluate any treatment plan submitted through eviti|Connect for such a payer.
4) The stratification described above may change to reflect new clinical data or changes in national/international guidelines.
For questions or concerns about the eviti application or the regimen selection available please feel free to contact the eviti Support Center at firstname.lastname@example.org or 1-888-678-0990 (toll free). Your inquiry will be directed to a clinician.